Moderna, Inc. vs Insmed Incorporated
A head-to-head of Moderna, Inc. (MRNA) and Insmed Incorporated (INSM) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | MRNA | INSM |
|---|---|---|
| Market Cap | $19.47B | $22.51B |
| P/E (TTM) | — | — |
| Forward P/E | -10.81 | 290.45 |
| P/S | 8.44 | 28.34 |
| P/B | 2.61 | 31.90 |
| EV/EBITDA | -6.46 | -23.96 |
| Dividend Yield | — | — |
| Profit Margin | -144.92% | -144.44% |
| Gross Margin | 54.84% | 79.73% |
| Operating Margin | -159.94% | -164.04% |
| Revenue Growth (YoY) | +263.55% | +229.62% |
| FCF Yield | -8.54% | -3.97% |
| Debt / Equity | 7.96 | 76.93 |
| Current Ratio | 2.41 | 4.47 |
Share:
Compare Moderna, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.